Using Serum Free Light Chain Measurement to Diagnose Myeloma in Patients with Severe Kidney Failure
Author Information
Author(s): Hutchison Colin A, Plant Tim, Drayson Mark, Cockwell Paul, Kountouri Melpomeni, Basnayake Kolitha, Harding Stephen, Bradwell Arthur R, Mead Graham
Primary Institution: University Hospital Birmingham
Hypothesis
Can serum free light chain measurements improve the diagnosis of multiple myeloma in patients with severe renal failure?
Conclusion
Serum free light chain measurements are a sensitive and specific method for identifying multiple myeloma in patients with acute renal failure.
Supporting Evidence
- All 41 patients diagnosed with multiple myeloma had abnormal serum free light chain ratios.
- The modified reference range increased the specificity of the assays from 93% to 99%.
- Monoclonal free light chains were identified in the urine from 23 of 24 patients assessed.
Takeaway
Doctors can use a blood test to check for certain proteins to help find out if someone has a type of cancer called myeloma, especially if their kidneys are not working well.
Methodology
The study assessed serum samples from 142 patients with new dialysis-dependent renal failure using serum protein electrophoresis and free light chain immunoassays.
Potential Biases
Potential bias due to the study being conducted at a single institution and the reliance on clinical diagnoses.
Limitations
The study did not include a diverse demographic representation and relied on a single center for data collection.
Participant Demographics
{"total":142,"multiple_myeloma":41,"male_percentage":39,"median_age":70,"ethnicity":{"Caucasian":85,"Afro-Caribbean":4,"South-Asian":8,"Other":3}}
Statistical Information
P-Value
p<0.001
Confidence Interval
CI: 0.98–1.00
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website